Home/Race Oncology/Dr. Peter Molloy
DP

Dr. Peter Molloy

Non-Executive Director

Race Oncology

Therapeutic Areas

Race Oncology Pipeline

DrugIndicationPhase
Bisantrene (RC220)Relapsed/Refractory Acute Myeloid Leukemia (AML)Phase 2